Eagle Pharma (EGRX) - Rasio Kapitalisasi Pasar marang Nilai Buku

Eagle Pharma - logo grafis emiten EGRX

Eagle Pharmaceuticals relies on external contractors for the production of injectables, which creates quality risks. The market-to-book ratio confirms the impact of this model, where the value of 0.11 corresponds to the current metric. Personnel are retained through a bonus system within narrow niches. The company is currently cutting R&D expenses and refinancing debt to stabilize its structure.

Nilai Pasar marang Nilai Buku eagleus.com (EGRX): kanggo periode 04.07.2022 - 12.10.2024

EGRX (Eagle Pharmaceuticals): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Kutipan saham eagleus.com|EGRX - Prakiraan gabungan firma investasi
- indikator kapitalisasi pasar:
Kapitalisasi pasar Eagle Pharma|EGRX - Nilai Total Perusahaan
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Siji Saham Eagle Pharmaceuticals|EGRX - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku eagleus.com|EGRX - Aset Perusahaan
- indikator beban utang lan likuiditas:
Total Utang marang Modal Eagle Pharmaceuticals|EGRX - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas eagleus.com|EGRX - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Eagle Pharma|EGRX - Gedhene kewajiban jangka dawa|Kewajiban jangka cendhak perusahaan Eagle Pharmaceuticals|Rasio cepet eagleus.com
- rincian bathi lan kelipatan pasar:
EGRX - Penghasilan resik
Analisis kabeh metrik perusahaan:Eagle Pharmaceuticals Inc., EGRX
Barang unggulan eagleus.com

Eagle Pharmaceuticals operates in the highly competitive injectable oncology segment. By analyzing the historical trend of the price-to-book ratio, one can assess the real value of the business. This coefficient determines the market premium paid per unit of the company's equity. For Eagle Pharmaceuticals (EGRX), this indicator reflects an asset discount amid legal costs and pressure from generics. Low values confirm undervaluation but signal risks regarding margin scaling.

Analisis pesaing Eagle Pharmaceuticals

OLMA (Olema Pharmaceuticals) - Rasio Kapitalisasi marang Aset Bersih|Rasio Kapitalisasi marang Nilai Buku PBYI|GLSI (Greenwich LifeSciences, Inc.) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku ZNTL|Rasio Nilai Pasar marang Nilai Buku MacroGenics Corp (MGNX)|PSTV (plustherapeutics.com) - Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku PCSA (Processa Pharmaceuticals, Inc.)